human
liver
react
hepat
c
viru
hcv
balanc
respons
consist
host
antiand
provir
activ
explor
subtl
host
respons
use
oligonucleotid
microarray
investig
differenti
gene
express
two
group
liver
sampl
high
low
hcv
load
differ
identifi
valid
gene
upregul
liver
high
hcv
load
includ
transmembran
proteas
serin
trypsin
inhibitor
inhibit
infect
cell
cellculturederiv
hcv
hcvcc
japanes
fulmin
hepat
isol
postbind
entri
step
trypsin
enhanc
hcvcc
infect
earli
stage
infect
sever
major
transmembran
serin
proteas
particular
furin
hepsin
detect
cell
cell
clone
stabli
express
wild
type
inact
gene
show
posit
neg
enhanc
suscept
hcvcc
infect
respect
enhanc
suscept
cell
confirm
knockdown
use
small
interf
rna
cellsurfac
proteas
activ
cell
markedli
activ
cleavag
qar
qgr
correspond
amino
acid
residu
conclus
cellsurfac
activ
trypsinlik
serin
proteas
activ
hcv
infect
postbind
entri
stage
host
transmembran
serin
proteas
may
involv
sensit
persist
pathogenesi
hcv
infect
possibl
target
antivir
therapi
hepatolog
human
liver
react
hepat
c
viru
hcv
balanc
respons
consist
host
antiand
provir
activ
explor
subtl
host
respons
use
oligonucleotid
microarray
investig
differenti
gene
express
two
group
liver
sampl
high
low
hcv
load
differ
identifi
valid
gene
upregul
liver
high
hcv
load
includ
transmembran
proteas
serin
trypsin
inhibitor
inhibit
infect
cell
cellculturederiv
hcv
hcvcc
japanes
fulmin
hepat
isol
postbind
entri
step
trypsin
enhanc
hcvcc
infect
earli
stage
infect
sever
major
transmembran
serin
proteas
particular
furin
hepsin
detect
cell
cell
clone
stabli
express
wild
type
inact
gene
show
posit
neg
enhanc
suscept
hcvcc
infect
respect
enhanc
suscept
cell
confirm
knockdown
use
small
interf
rna
cellsurfac
proteas
activ
cell
markedli
activ
cleavag
qar
qgr
correspond
amino
acid
residu
conclus
cellsurfac
activ
trypsinlik
serin
proteas
activ
hcv
infect
postbind
entri
stage
host
transmembran
serin
proteas
may
involv
sensit
persist
pathogenesi
hcv
infect
possibl
target
antivir
therapi
hepatolog
h
epat
c
viru
hcv
caus
agent
chronic
hepat
liver
cirrhosi
hepatocellular
carcinoma
hcc
therapi
chronic
hepat
c
markedli
progress
follow
recent
approv
directact
antivir
agent
administ
addit
standard
care
pegyl
interferon
ifn
plu
ribavirin
howev
pathogenesi
chronic
liver
diseas
caus
hcv
infect
remain
well
elucid
instanc
type
host
respons
induc
hcv
infect
contribut
hcv
pathogenesi
mechan
action
analysi
hcvinduc
chang
host
transcriptom
may
help
resolv
issu
respons
cell
infect
hcv
examin
vitro
vivo
liver
respons
chimpanze
patient
acut
resolv
chronic
hcv
infect
examin
hcv
infect
elev
ifnstimul
gene
isg
much
notabl
vivo
vitro
cell
defect
respons
ifn
mutat
retino
acidinduc
gene
analysi
gene
express
profil
cell
reveal
antivir
respons
proinflammatori
proapoptot
signal
also
provir
respons
requir
hcv
replic
secret
cellular
level
complex
virushost
interact
may
relev
pathogenesi
hcv
infect
includ
steatosi
fibrosi
persist
analysi
tissuelevel
respons
hcv
infect
vivo
identifi
gene
respons
hcv
infect
includ
promot
inflammatori
cell
infiltr
ifn
respons
use
differenti
hybrid
complementari
dna
cdna
librari
also
isol
two
isg
gene
markedli
upregul
chimpanze
liver
acut
phase
hcv
infect
major
histocompat
complex
class
c
ifnainduc
protein
thu
clear
ifn
respons
actual
activ
hcv
infect
vivo
variou
downstream
respons
contribut
hcvhost
interact
current
isg
includ
mention
investig
detail
role
critic
molecul
intraand
extracellular
innat
immun
hcv
infect
becom
clear
howev
remain
differenti
express
gene
whose
function
unknown
gene
express
profil
human
liver
use
cultur
cell
elucid
natur
hcvhost
interact
studi
control
host
antivir
respons
level
entir
organ
identifi
critic
factor
respons
hcv
control
human
liver
use
determin
subtl
differ
host
respons
differ
hcv
load
liver
rather
mark
differ
human
liver
without
hcv
infect
achiev
investig
differ
human
liver
chronic
hepat
contain
high
low
load
hcv
compar
gene
express
profil
liver
contain
quit
differ
hcv
load
focus
limit
critic
factor
govern
hcvhost
interact
vivo
verifi
differenti
gene
express
two
group
liver
sampl
function
gene
potenti
antior
provir
effect
analyz
hcv
infect
studi
identifi
gene
upregul
liver
high
hcv
load
among
sever
gene
unknown
function
hcv
infect
character
transmembran
proteas
serin
new
host
factor
activ
hcv
infect
liver
specimen
cell
hcvposit
liver
sampl
obtain
surgic
resect
nontumor
liver
tissu
patient
hcc
patient
solitari
hcc
less
cm
diamet
show
metastasi
lymph
node
organ
quantifi
hcvrna
concentr
liver
follow
normal
ribosom
rna
classifi
sampl
three
group
accord
hcv
load
measur
arbitrari
unit
hcv
rna
high
middl
low
patient
chronic
hepat
liver
cirrhosi
subject
belong
hcvhigh
case
hcvlow
group
case
support
tabl
hcvneg
liver
sampl
obtain
nontumor
liver
tissu
patient
hepat
metastas
colon
cancer
written
inform
consent
obtain
patient
studi
protocol
previous
approv
ethic
committe
school
accord
declar
helsinki
cell
japanes
fulmin
hepat
isol
hcv
subgenom
replicon
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
contain
mgml
mgml
invitrogen
carlsbad
ca
respect
reagent
human
plasma
phosphoramidon
bestatin
nacetylatedtrypsin
purchas
sigmaaldrich
st
loui
mo
trypsin
porcin
pancrea
baee
unitsmg
soybean
trypsin
inhibitor
sbti
baee
unit
mg
benzenesulfonyl
fluorid
hydrochlorid
aebsf
calpain
inhibitor
pepstatin
xtremegen
hp
roch
diagnost
gmbh
mannheim
germani
small
interf
rna
sirna
dharmacon
thermo
fisher
scientif
waltham
rabbit
monoclon
antibodi
ab
abcam
cambridg
uk
secondari
ab
conjug
alexa
fluor
invitrogen
bromid
mtt
purchas
dojindo
kumamoto
japan
comprehens
analysi
messeng
rna
express
summari
messeng
rna
mrna
express
shown
support
fig
five
random
sampl
hcvhigh
hcvlow
group
nontumor
liver
tissu
without
liver
cirrhosi
support
tabl
analyz
gene
express
profil
also
analyz
gene
express
seven
three
sampl
hcvhigh
hcvlow
group
nontumor
liver
tissu
liver
cirrhosi
support
tabl
biotinlabel
complementari
rna
crna
synthes
total
rna
use
megascript
kit
ambion
austin
tx
fragment
crna
hybrid
human
genom
plu
array
affymetrix
santa
clara
ca
compris
probe
wash
stain
fluidic
station
affymetrix
array
scan
scanner
affymetrix
accord
protocol
describ
affymetrix
genechip
express
analysi
manual
signal
gene
analyz
use
genespr
version
silicon
genet
redwood
ca
support
tabl
show
candid
differenti
express
gene
isol
chronic
hepat
liver
sampl
without
liver
cirrhosi
quantif
mrna
total
rna
isol
liver
tissu
subject
dnase
treatment
follow
cdna
synthesi
describ
previous
synthesi
cdna
cultur
cell
perform
use
mg
total
rna
revertra
ace
qpcr
rt
master
mix
gdna
remov
toyobo
osaka
japan
express
level
specif
mrna
determin
quantit
realtim
polymeras
chain
reaction
qpcr
use
sybr
green
taqman
gene
express
assay
primer
sequenc
sybr
green
qpcr
shown
togeth
taqman
gene
express
assay
id
support
tabl
immunohistochem
stain
formalinfix
paraffinembed
thin
section
mm
thick
treat
mm
citrat
buffer
ph
c
minut
antigen
retriev
block
hydrogen
peroxid
follow
skim
milk
phosphatebuff
salin
pb
minut
c
section
incub
mgml
ab
c
minut
stain
histofin
simpl
stain
max
po
multi
nichirei
tokyo
japan
minut
room
temperatur
section
react
dab
chromogen
wako
pure
chemic
industri
ltd
tokyo
japan
counterstain
hematoxylin
infect
cellculturederiv
hcv
cellculturederiv
hcv
hcvcc
deriv
genotyp
prepar
previous
describ
cell
seed
plate
contain
coverslip
incub
overnight
c
cell
inocul
hcvcc
copi
hcv
rna
focusform
unit
c
hour
ml
pb
remov
inoculum
cell
incub
complet
medium
day
cultur
coverslip
rins
pb
stain
hcv
protein
alexa
fluor
describ
previous
nuclei
stain
dapi
invitrogen
stain
cell
visual
biorevo
microscop
keyenc
osaka
japan
fluoresc
microscop
olympu
tokyo
japan
hcv
infect
determin
number
foci
contain
hcvposit
cell
cell
number
occasion
decreas
stain
number
foci
normal
total
number
cell
use
area
dapiposit
nuclei
instead
cell
number
gene
knockdown
sirna
cultiv
cell
plate
cell
transfect
nm
sirna
use
ml
dharmafect
cell
cultur
complet
medium
harvest
infect
hcvcc
hour
posttransfect
stabl
cell
clone
produc
type
contain
cdna
encod
human
wildtyp
wt
encod
inact
mutant
digest
ecori
noti
isol
cdna
fragment
insert
ecorinoti
site
vector
contain
blasticidinresist
gene
invitrogen
vector
use
neg
control
cell
transfect
complex
plasmid
xtremegen
stabl
clone
transfect
cell
establish
cultur
mgml
blasticidin
clone
screen
immunofluoresc
stain
ab
secondari
ab
conjug
alexa
fluor
fixat
paraformaldehyd
room
temperatur
minut
assess
proteas
activ
cellsurfac
serin
proteas
activ
assess
use
follow
synthet
peptid
analog
tbutyloxycarboni
boc
mca
bocrvrrmca
bocfsrmca
bocqgrmca
bocqarmca
bocqrrmca
peptid
institut
inc
osaka
japan
bocqsrmca
genenet
fukuoka
japan
precultur
cell
hour
black
plate
follow
pb
wash
ml
mm
peptid
substrat
optimem
ad
cell
fluoresc
releas
aminomethyl
coumarin
measur
immedi
use
infinit
tecan
schweiz
ag
annedorf
switzerland
nm
excitationemiss
wavelength
everi
minut
hour
c
fluoresc
normal
cell
number
determin
mtt
assay
enzym
activ
assess
kinet
specif
inhibit
sbti
dosedepend
manner
support
fig
cell
fusion
induc
cleavag
influenza
viru
hemagglutinin
celltocel
fusion
assess
describ
previous
stabl
cell
clone
grown
plate
transfect
mixtur
mg
hemagglutinin
ha
subtyp
express
plasmid
pcaggsha
mg
enhanc
green
fluoresc
protein
egfp
express
plasmid
pcaggsegfp
use
xtremegen
hp
dna
transfect
reagent
day
posttransfect
cell
incub
dmem
absenc
exogen
trypsin
supplement
mgml
acetylatedtrypsin
sigmaaldrich
day
posttransfect
cell
wash
pb
treat
prewarm
lowph
buffer
mm
nacl
mm
sodium
citrat
ph
minut
lowph
buffer
replac
dmem
contain
fb
cell
incub
c
hour
cell
observ
use
fluoresc
microscop
percentag
fluoresc
area
measur
use
imagej
softwar
version
nation
institut
health
bethesda
md
statist
analysi
mannwhitney
u
test
use
analyz
twogroup
comparison
student
test
use
experi
vitro
p
valu
less
consid
statist
signific
express
increas
hcvhigh
group
liver
investig
antiand
provir
host
respons
hcv
infect
human
liver
use
oligonucleotid
microarray
examin
differenti
gene
express
two
group
liver
sampl
contain
high
low
hcv
load
exclud
involv
variabl
divid
nontumor
liver
tissu
two
group
one
one
without
liver
cirrhosi
obtain
patient
chronic
hepat
earli
stage
hcc
hcv
load
differ
markedli
two
group
clinicopatholog
featur
significantli
differ
accord
statist
analys
support
tabl
identifi
candid
gene
liver
chronic
hepat
presenc
absenc
liver
cirrhosi
verifi
gene
upregul
liver
high
hcv
load
use
chronic
hepat
liver
without
liver
cirrhosi
support
fig
support
tabl
gene
seven
isg
oasl
oligoadenyl
synthetaselik
isg
unknown
function
inhibit
hcv
replic
vitro
describ
previous
thu
gene
upregul
hcvhigh
group
relat
antivir
respons
howev
known
whether
sever
gene
associ
antior
provir
respons
function
infect
among
gene
upregul
hcvhigh
group
support
tabl
focus
member
hepsin
hpn
subfamili
type
ii
transmembran
serin
proteas
one
top
three
differenti
express
gene
addit
oasl
gene
lowest
p
valu
mannwhitney
u
test
show
chang
current
understand
physiolog
function
type
ii
transmembran
serin
proteas
highlight
contribut
human
diseas
seem
import
determin
whether
involv
life
cycl
hcv
pathogenesi
upregul
hcvhigh
liver
compar
hcvlow
hcvneg
liver
confirm
qpcr
fig
protein
also
highli
express
hcvhigh
liver
shown
immunohistochemistri
ihc
local
heterogen
liver
tissu
strongli
posit
apic
membran
hepatocyt
fig
inhibitor
trypsinlik
serin
proteas
inhibit
earli
stage
hcvcc
infect
vitro
investig
involv
cellsurfac
trypsinlik
serin
proteas
hcv
infect
vitro
analyz
hcv
infect
inocul
hcvcc
hour
presenc
sever
differ
proteas
inhibitor
follow
remov
inoculum
cultur
day
among
inhibitor
five
class
proteas
serin
proteas
inhibitor
includ
sbti
aebsf
inhibit
infect
dosedepend
manner
fig
confirm
role
trypsinlik
serin
proteas
cell
surfac
earli
stage
hcv
infect
hcvcc
inocul
presenc
trypsin
hcv
infect
enhanc
mgml
trypsin
fig
effect
cell
morpholog
determin
step
earli
stage
infect
attach
entri
hcvcc
cell
inhibit
sbti
hcvcc
incub
cell
c
first
hour
attach
remov
hcvcc
inoculum
cell
incub
c
hour
allow
entri
fig
cell
incub
day
determin
hcv
infect
stain
hcvposit
cell
even
sbti
present
second
step
entri
hcv
infect
inhibit
fig
hcv
replic
postentri
inhibit
sbti
fig
result
suggest
trypsinlik
serin
proteas
involv
earli
stage
infect
particularli
entri
hcvcc
cell
sbti
also
inhibit
hcv
infect
extent
chimer
virus
contain
genotyp
structur
gene
statist
signific
support
fig
cell
involv
hcvcc
infect
ask
type
cellsurfac
serin
proteas
express
cell
whether
express
proteas
increas
decreas
hcvcc
infect
determin
mrna
level
transmembran
serin
proteas
preand
postinfect
hcvcc
furin
hpn
express
cell
absent
fig
furin
mrna
upregul
infect
hcvcc
fig
hand
normal
human
liver
predominantli
express
four
proteas
hpn
abund
follow
furin
descend
order
support
fig
upregul
hcvhigh
liver
support
fig
fig
cellsurfac
serin
proteas
cell
measur
use
synthet
fluorogen
substrat
contain
variou
amino
acid
sequenc
cleavag
site
fig
highest
proteas
activ
qsr
activ
qar
qrr
fsr
rvrr
similar
level
less
half
qsr
substrat
specif
profil
cell
quit
differ
pancreat
trypsin
fig
knockdown
furin
hpn
respect
sirna
effect
focu
format
infect
cell
support
fig
hcvhigh
high
group
mrna
level
quantifi
qpcr
use
standard
curv
serial
dilut
standard
cdna
quantiti
normal
rrna
express
arbitrari
unit
hcv
nontumor
liver
patient
hepat
metastas
colon
cancer
hcv
nontumor
liver
patient
contain
low
high
viral
load
respect
shown
support
tabl
two
asterisk
indic
signific
differ
p
mannwhitney
u
test
b
ihc
protein
nontumor
liver
low
high
hcv
load
brown
immunostain
dab
blue
counterstain
nuclei
hematoxylin
bar
mm
fig
hcv
infect
presenc
proteas
inhibitor
trypsin
cell
inocul
hcvcc
presenc
variou
proteas
inhibitor
serin
proteas
cystein
proteas
metal
proteas
aspart
proteas
aminopeptidas
trypsin
concentr
indic
hour
inoculum
remov
cell
cultur
fresh
complet
medium
day
hcv
infect
determin
number
foci
contain
hcvposit
cell
control
experi
conduct
absenc
inhibitor
trypsin
infect
express
experi
perform
duplic
two
independ
experi
gave
result
result
express
mean
standard
error
repres
experi
p
p
student
test
respect
result
suggest
serin
proteas
furin
hpn
involv
suscept
cell
hcv
infect
activ
hcvcc
infect
investig
whether
involv
hcv
infect
establish
stabl
cell
clone
produc
wt
inact
mutant
fig
b
cellsurfac
proteas
clone
specif
activ
substrat
qar
qgr
put
substrat
proteas
neg
control
clone
fig
influenza
viru
ha
introduc
fig
sbti
inhibit
earli
stage
hcv
infect
two
step
hcv
bind
entri
separ
incub
c
c
respect
cell
precultur
day
hcvcc
inocul
presenc
absenc
mgml
sbti
c
hour
remov
inoculum
cell
incub
fresh
complet
medium
presenc
absenc
mgml
sbti
c
hour
remov
sbti
cell
cultur
fresh
complet
medium
hour
hcv
infect
determin
describ
fig
control
experi
without
sbti
b
sbti
bind
step
c
sbti
entri
sbti
step
e
sbti
inocul
two
independ
experi
gave
result
repres
shown
data
shown
mean
standard
error
duplic
experi
p
p
student
test
respect
b
hcv
rna
replic
hcv
replicon
cell
treatment
variou
concentr
sbti
hcv
replicon
cell
treat
sbti
mgml
c
hour
remov
sbti
cell
incub
fresh
complet
medium
day
hcv
rna
determin
four
time
point
normal
dehydrogenas
express
rel
quantit
method
rel
hcv
rna
express
ratio
replicon
cell
treatment
sbti
fig
mrna
express
transmembran
serin
proteas
cellsurfac
serin
proteas
activ
cell
mrna
level
follow
serin
proteas
quantifi
qpcr
type
serin
proteas
furin
subfamili
type
ii
hpn
matriptas
subfamili
type
ii
suppress
tumorigen
corin
subfamili
type
ii
corin
hat
subfamili
type
ii
human
airway
trypsinlik
proteas
hat
hcv
cell
prepar
inocul
hcvcc
hcv
rna
copi
cell
precultur
day
cultur
fresh
complet
medium
day
one
passag
hcv
cell
infect
cultur
way
rel
gene
express
express
percentag
ratio
express
target
gene
dehydrogenas
insert
panel
fluoresc
stain
hcv
protein
green
alexa
fluor
nuclei
blue
dapi
p
student
test
b
cellsurfac
serin
proteas
activ
cell
measur
use
variou
peptid
analogmca
substrat
fluoresc
releas
determin
hour
normal
cell
number
determin
mtt
assay
proteas
activ
ng
per
ml
pancreat
trypsin
also
measur
peptid
minut
data
shown
mean
standard
error
duplic
experi
transfect
express
plasmid
cell
clone
ha
induc
celltocel
fusion
cell
clone
fig
e
fusion
depend
activ
induc
neg
cell
clone
howev
trypsin
treatment
induc
cell
fusion
neg
cell
clone
immunoblot
show
wtdepend
autocleavag
peptid
gener
ctermin
activ
domain
cell
clone
cell
clone
support
fig
thu
cell
clone
show
function
proteas
activ
synthet
peptid
vitro
nativ
substrat
vivo
hcv
infect
also
enhanc
wtdepend
manner
cell
clone
cell
clone
sensit
hcv
infect
neg
cell
clone
fig
mrna
knock
sirna
proteas
activ
qar
qgr
markedli
reduc
cell
clone
fig
b
proteas
activ
qsr
fsr
express
mrna
mrna
level
quantifi
qpcr
stabl
cell
clone
produc
wild
mut
stabl
clone
transfect
vector
use
control
quantiti
mrna
normal
gapdh
mrna
rel
quantit
method
b
stain
stabl
cell
clone
shown
stain
red
nuclei
blue
dapi
cell
ratio
tm
mut
wild
respect
c
cellsurfac
proteas
activ
variou
peptid
analogmca
substrat
four
stabl
cell
clone
shown
examin
surfac
proteas
activ
describ
fig
cell
fusion
induc
influenza
viru
ha
four
stabl
cell
clone
shown
transfect
haexpress
plasmid
egfpexpress
plasmid
treat
without
trypsin
day
treatment
lowph
buffer
cell
observ
use
fluoresc
microscop
e
percentag
fluoresc
area
fig
data
shown
mean
standard
deviat
three
differ
microscop
field
area
p
p
student
test
respect
f
hcv
infect
four
stabl
cell
clone
infect
hcvcc
number
hcvposit
cell
foci
measur
normal
area
dapi
p
student
test
abbrevi
gapdh
dehydrogenas
also
respond
knockdown
wt
fig
enhanc
hcv
infect
also
reduc
level
neg
control
knockdown
fig
abil
hcv
infect
cell
chang
even
though
mrna
markedli
knock
fig
c
thu
proteas
activ
activ
hcvcc
infect
vitro
found
gene
significantli
elev
nontumor
noncirrhot
liver
chronic
hepat
contain
high
hcv
load
compar
contain
low
hcv
load
support
tabl
support
fig
unexpectedli
wellknown
antivir
gene
rather
highli
express
liver
hcvhigh
load
includ
isg
inflammationimmun
responserel
gene
antivir
gene
exampl
markedli
upregul
typic
isg
oasl
support
tabl
function
initi
unknown
inhibit
replic
hcvcc
describ
previous
interestingli
epithelialmesenchym
transit
emt
relat
gene
notabl
upregul
support
tabl
activ
emt
state
inhibitori
tight
junctionmedi
viral
infect
measl
viru
infect
like
hcv
infect
thu
compar
studi
show
among
two
possibl
host
respons
hcv
infect
antiand
provir
respons
antivir
respons
chief
respons
liver
high
hcv
load
antivir
respons
consid
result
high
hcv
load
wherea
provir
respons
caus
high
hcv
load
persist
high
hcv
load
may
caus
unknown
provir
mechan
respons
suffici
reduc
hcv
load
six
gene
includ
isg
overlap
previou
studi
compar
hcvneg
posit
liver
support
tabl
gene
first
identifi
studi
use
elucid
mechan
hcv
control
persist
human
liver
gene
whose
role
unknown
hcv
control
persist
remain
describ
ask
quit
significantli
upregul
hcvhigh
liver
associ
hcv
infect
vitro
demonstr
trypsinlik
serin
proteas
involv
earli
stage
hcv
infect
activ
hcvcc
infect
vitro
member
type
ii
transmembran
serin
proteas
famili
activ
proteas
airway
epithelium
influenza
viru
infect
cleav
surfac
glycoprotein
ha
produc
fusion
peptid
facilit
spread
viru
thu
tissu
express
affect
viral
pneumotrop
pathogen
recent
also
shown
contribut
spread
respiratori
virus
sever
acut
respiratori
syndrom
coronaviru
parainfluenza
virus
cleav
viral
spike
protein
f
protein
respect
lead
celltoviru
celltocel
fusion
current
report
use
mice
indic
essenti
influenza
viru
pathogenesi
mice
known
yet
target
protein
hcv
infect
whether
fusion
activ
induc
preferenti
local
apic
membran
hepatocyt
human
liver
high
hcv
load
fig
proteas
activ
detect
surfac
cell
fig
therefor
might
also
involv
hcv
entri
spread
close
tight
junction
hepatocyt
human
liver
compon
occludin
ocln
key
molecul
hcv
entri
spread
hand
cleav
newli
synthes
ha
secretori
pathway
within
influenza
virusinfect
cell
also
play
role
releas
porcin
epidem
diarrhea
viru
determin
whether
activ
occur
earli
stage
hcv
entri
andor
spread
late
stage
hcv
releas
crucial
identifi
protein
cleav
activ
hcv
infect
studi
suggest
possibl
cleavagesit
sequenc
target
qar
qgr
sensit
sequenc
examin
fig
qsr
qtr
also
sensit
sequenc
shown
nativ
protein
target
activ
form
gener
autocleavag
qsr
produc
stabli
transfect
cell
enzymedepend
manner
support
fig
hamedi
fusion
occur
use
subtyp
ha
cleavag
site
qtr
fig
e
thu
broadli
activ
sever
cleavagesit
sequenc
qxr
qar
qgr
sensit
rvrr
clearli
resist
fig
recent
substrat
character
use
variou
ha
subtyp
subtyp
ha
examin
cleav
vari
effici
survey
cleavagesit
sequenc
qe
xr
surfac
protein
lipoviroparticl
host
entri
factor
hcv
infect
identifi
sever
possibl
protein
candid
target
apolipoprotein
apo
b
apo
lowdens
lipoprotein
receptor
scaveng
receptor
class
b
type
ocln
hcv
fusion
process
depend
ph
lipid
composit
viral
target
membran
hcv
though
remain
unclear
whether
cellular
proteas
requir
step
identifi
target
help
highlight
novel
activ
mechan
hcv
infect
major
endogen
transmembran
serin
proteas
furin
hpn
involv
infect
cell
hcvcc
support
fig
demonstr
cellsurfac
serin
proteas
cell
mainli
activ
qsr
secondli
rvrr
qar
cleavagesit
sequenc
nearli
neg
qgr
fig
exogen
trypsin
unabl
cleav
rvrr
fig
also
enhanc
hcv
infect
find
suggest
endogen
transmembran
serin
proteas
furin
hpn
preferenti
cleav
qgr
rvrr
like
help
hcvcc
infect
similar
conclus
demonstr
upregul
human
liver
contain
hcvhigh
load
activ
hcvcc
infect
vitro
cellsurfac
trypsinlik
serin
proteas
requir
earli
event
hcv
infectionhcv
entri
result
suggest
host
transmembran
serin
proteas
support
hcv
entri
cell
surfac
human
liver
cell
target
key
molecul
provir
infect
discoveri
provid
new
insight
antivir
strategi
